RedHill, Kukbo Ink Oral Opaganib Licensing Pact For COVID-19 In South Korea
RedHill Biopharma Ltd (NASDAQ:RDHL) has entered into an exclusive license agreement with Kukbo Co Ltd for oral opaganib to treat COVID-19 in South Korea. Under the terms of the license agreement, which follows the previously announced strategic investment by Kukbo, RedHill will receive an upfront payment of $1.5 million. Redhill is eligible for up to $5.6 million…
Benzinga ·
Benzinga
